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Articles
Eﬀ ect of amiloride, or amiloride plus hydrochlorothiazide, 
versus hydrochlorothiazide on glucose tolerance and blood 
pressure (PATHWAY-3): a parallel-group, double-blind 
randomised phase 4 trial
Morris J Brown, Bryan Williams, Steve V Morant, David J Webb, Mark J Caulﬁ eld, J Kennedy Cruickshank, Ian Ford, Gordon McInnes, Peter Sever, 
Jackie Salsbury, Isla S Mackenzie, Sandosh Padmanabhan, Thomas M MacDonald, for the British Hypertension Society’s Prevention and 
Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group*
Summary
Background Potassium depletion by thiazide diuretics is associated with a rise in blood glucose. We assessed whether 
addition or substitution of a potassium-sparing diuretic, amiloride, to treatment with a thiazide can prevent glucose 
intolerance and improve blood pressure control.
Methods We did a parallel-group, randomised, double-blind trial in 11 secondary and two primary care sites in the UK. 
Eligible patients were aged 18–80 years; had clinic systolic blood pressure of 140 mm Hg or higher and home systolic 
blood pressure of 130 mmHg or higher on permitted background drugs of angiotensin-converting enzyme inhibitors, 
angiotensin-receptor blockers, β blockers, calcium-channel blockers, or direct renin inhibitors (previously untreated 
patients were also eligible in speciﬁ c circumstances); and had at least one component of the metabolic syndrome in 
addition to hypertension. Patients with known diabetes were excluded. Patients were randomly assigned (1:1:1) to 
24 weeks of daily oral treatment with starting doses of 10 mg amiloride, 25 mg hydrochlorothiazide, or 5 mg amiloride 
plus 12·5 mg hydrochlorothiazide; all doses were doubled after 12 weeks. Random assignment was done via a central 
computer system. Both participants and investigators were masked to assignment. Our hierarchical primary endpoints, 
assessed on a modiﬁ ed intention-to-treat basis at 12 and 24 weeks, were the diﬀ erences from baseline in blood glucose 
measured 2 h after a 75 g oral glucose tolerance test (OGTT), compared ﬁ rst between the hydrochlorothiazide and 
amiloride groups, and then between the hydrochlorothiazide and combination groups. A key secondary endpoint was 
change in home systolic blood pressure at 12 and 24 weeks. This trial is registered with ClinicalTrials.gov, number 
NCT00797862, and the MHRA, Eudract number 2009-010068-41, and is now complete.
Findings Between Nov 18, 2009, and Dec 15, 2014, 145 patients were randomly assigned to amiloride, 146 to 
hydrochlorothiazide, and 150 to the combination group. 132 participants in the amiloride group, 134 in the 
hydrochlorothiazide group, and 133 in the combination group were included in the modiﬁ ed intention-to-treat analysis. 
2 h glucose concentrations after OGTT, averaged at 12 and 24 weeks, were signiﬁ cantly lower in the amiloride group 
than in the hydrochlorothiazide group (mean diﬀ erence –0∙55 mmol/L [95% CI –0∙96 to –0∙14]; p=0∙0093) and in the 
combination group than in the hydrochlorothiazide group (–0∙42 mmol/L [–0∙84 to –0∙004]; p=0∙048). The mean 
reduction in home systolic blood pressure during 24 weeks did not diﬀ er signiﬁ cantly between the amiloride and 
hydrochlorothiazide groups, but the fall in blood pressure in the combination group was signiﬁ cantly greater than that 
in the hydrochlorothiazide group (p=0∙0068). Hyperkalaemia was reported in seven (4·8%) patients in the amiloride 
group and three (2·3%) patients in the combination group; the highest recorded potassium concentration was 
5∙8 mmol/L in a patient in the amiloride group. 13 serious adverse events occurred but the frequency did not diﬀ er 
signiﬁ cantly between groups.
Interpretation The combination of amiloride with hydrochlorothiazide, at doses equipotent on blood pressure, 
prevents glucose intolerance and improves control of blood pressure compared with montherapy with either drug. 
These ﬁ ndings, together with previous data about morbidity and mortality for the combination, support ﬁ rst-line use 
of amiloride plus hydrochlorothiazide in hypertensive patients who need treatment with a diuretic.
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Introduction
The optimum diuretic for hypertension remains 
uncertain. Disparity has been growing between the drugs 
and doses proven to reduce risk of stroke, myocardial 
infarction, and heart failure, and those recommended by 
guidelines.1,2 This move away from recommendation of 
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diuretics in guidelines was driven by an awareness that 
thiazide and thiazide-like diuretics can increase risk of 
developing type 2 diabetes.3–7 The risk seems linked to 
potassium depletion, and might be avoided by use of 
potassium-sparing diuretics,3,4,8 which are conventionally 
thought to be the weakest class of diuretic because most 
ﬁ ltered sodium is reabsorbed upstream of their site of 
action in the nephron. But potassium-sparing diuretics 
target a common site of sodium retention in 
hypertension, and might be essential in the prevention of 
compensatory responses to the more proximally acting 
thiazide and loop diuretics.9 Thus, the hypothesis arose 
for the present study that an adequate dose of potassium-
sparing diuretic would have opposite eﬀ ects on 
potassium and glucose to those of a thiazide diuretic, but 
would have similar or additional eﬀ ects on blood 
pressure when the two were compared or combined.
The prevailing view in the 1990s and 2000s was that, at 
low doses, thiazides did not cause metabolic con-
sequences but remained maximally eﬃ  cacious at 
lowering blood pressure.10 Such a view was initially 
supported by under-powered comparisons of doses, in 
which no diﬀ erence in eﬀ ects on blood pressure were 
reported.11,12 However, an apparent dose–response 
correlation for blood pressure was rediscovered during 
treatment titration for an outcome comparison of 
diuretics with calcium-channel blockers, and this relation 
was conﬁ rmed by a formal, crossover comparison of 
doses in the Spironolactone, Amiloride, Losartan, 
Thiazide (SALT) study.13,14 The results of SALT also showed 
the potential value of potassium-sparing diuretics as an 
alternative to high-dose thiazides. However, in practice, 
concerns about hyperkalaemia limit the use of potassium-
sparing diuretics, especially in an era when most patients 
are receiving a renin–angiotensin system (RAS) blocker. 
Additionally, without proof that potassium-sparing 
diuretics are not associated with glucose intolerance, or 
indeed that they prevent major complications of 
hypertension, drugs such as spironolactone have not 
been included as options before stage 4 hypertension in 
most national guidelines, still less a replacement for 
thiazides as ﬁ rst-line treatment.11,12,15,16
Panel: Research in context
Evidence before this study
We searched MEDLINE and Ovid with the terms “thiazide 
diuretic”, “potassium”, and “glucose tolerance” under the 
medical subject headings “diabetes” and “hypertension” for 
observational studies or clinical trials published in English of 
diuretic use, diabetes, and glucose tolerance in hypertension. 
We did our last search on July 23, 2015. A network 
meta-analysis by Elliott and Meyer of incident diabetes in 
22 clinical trials of antihypertensive drugs involving 
143 153 participants showed that placebo groups had a lower 
odds ratio of developing diabetes (0·77, 95% CI 0·63–0·94) 
when compared with thiazide-assigned groups. In a 
retrospective meta-analysis by Zillich and colleagues, 
hypokalaemia and hyperglycaemia were signiﬁ cantly associated 
in patients given thiazide diuretics. There was an average 
reduction in serum potassium of 0·23 mmol/L and an increase 
in glucose of 3·26 mg/dL in studies in which potassium 
supplements or potassium-sparing drugs were used. In studies 
in which potassium supplements or potassium-sparing drugs 
were not used, the average reduction in serum potassium 
concentrations was 0·37 mmol/L, and the increase in serum 
glucose was 6·01 mg/dL (p<0·03). A quantitative review by the 
National Heart, Lung, and Blood Institute in 2008 cast some 
doubt on the strength of the observational studies that ﬁ rst led 
to recognition of the thiazide association with diabetes, and 
investigators noted that the strongest evidence for an adverse 
eﬀ ect of thiazides was in prospective outcome comparisons 
with placebo. The conclusion was that prospective studies 
should be done to investigate the hypothesis that 
hypokalaemia is the mediator of thiazide-induced 
dysglycaemia. Since 2008, diuretic doses and use have fallen 
because of concerns about metabolic consequences.
Added value of this study
In our study we compared a potassium-sparing diuretic, a 
potassium-losing diuretic, and a combination of the two during 
24 weeks in 441 patients who were either previously untreated 
or taking angiotensin-converting enzyme inhibitors, 
angiotensin-receptor blockers, or calcium-channel blockers. Our 
results supported our hypothesis that thiazide-induced glucose 
intolerance, as shown by 2 h glucose concentrations in oral 
glucose tolerance tests, would not occur in the absence of 
potassium depletion. Our results do not completely prove that 
potassium depletion causes the eﬀ ect of thiazide on glucose 
tolerance, but show that it is possible to potentiate the beneﬁ t 
of two classes of diuretic on blood pressure while cancelling out 
undesired eﬀ ects of thiazides on glucose and potassium 
concentrations.
Implications of all the available evidence
At an adequate dose (10–20 mg), amiloride is as eﬃ  cacious as 
25–50 mg hydrochlorothiazide, and is not associated with 
undesirable metabolic consequences. The combination of 
amiloride and hydrochlorothiazide was already known, from 
the Medical Research Council’s Elderly trial and INSIGHT, to be 
more eﬃ  cacious than comparator drugs at preventing some 
complications of hypertension; however, the 2·5–5 mg dose of 
amiloride given in these studies was inadequate to prevent 
hydrochlorothiazide-associated hypokalaemia or diabetes. We 
propose that the amiloride–hydrochlorothiazide combination 
tested in this study should be considered in patients taking 
either an angiotensin-converting enzyme inhibitor, an 
angiotensin-receptor blocker, or a calcium-channel blocker as a 
ﬁ rst-line treatment for hypertension.
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In combination with a thiazide diuretic, however, 
amiloride has been used for many years, and in two 
studies13,17 of morbidity and mortality, primary or 
secondary outcomes were signiﬁ cantly better with an 
amiloride–hydrochlorothiazide combination than with a 
calcium-channel blocker or a β blocker. But the low dose 
of amiloride in the widely available ﬁ xed-dose 
combination used in these studies is insuﬃ  cient to 
prevent hypo kalaemia. Furthermore, the overall dose of 
amiloride–hydrochlorothiazide needed to achieve the 
same reduction in blood pressure produced by the use of 
a calcium-channel blocker resulted in a 25% excess of 
new-onset diabetes in a previous trial.13
In the Study of Trandolapril/verapamil SR [sustained 
release] and Insulin Resistance (STAR),18 200 obese 
patients were randomly assigned to receive either an 
angiotensin-converting enzyme (ACE) inhibitor plus a 
calcium-channel blocker or an angiotensin-receptor 
blocker (ARB) plus a low-dose thiazide diuretic. After 
12 weeks, the ARB–diuretic group had signiﬁ cantly higher 
2 h glucose concentrations on an oral glucose tolerance 
test (OGTT). Furthermore, pilot studies19,20 showed that 
high doses of amiloride might be safely used in patients 
taking a RAS blocker, and have neutral or beneﬁ cial eﬀ ects 
on glucose tolerance. These studies informed the duration 
and size of our three-way, randomised, parallel-group 
study, the British Hypertension Society’s Prevention and 
Treatment of Hypertension with Algorithm-based Therapy 
(PATHWAY) 3 study, in which we compared the eﬀ ects of 
hydrochlorothiazide with those of amiloride, either alone 
or in combination, on glucose tolerance and blood 
pressure.
Methods
Study design and participants
PATHWAY-3 was a 24 week, parallel-group, randomised, 
double-blind, phase 4 trial done by the British 
Hypertension Society Research Network of Investigators 
at 11 secondary care and two primary care centres in the 
UK. The study design and rationale have been published 
previously (appendix).21
Eligible patients were aged 18–80 years and had clinic 
systolic blood pressure of 140 mmHg or higher, home 
systolic blood pressure of 130 mm Hg or higher, an 
indication for diuretic treatment, such as high systolic 
pressure despite treatment with an RAS blocker, and at 
least one component of the metabolic syndrome in 
addition to hypertension. Any permutation of ACE 
inhibitors, ARBs, β blockers, calcium-channel blockers, 
and direct renin inhibitors was permitted as background 
treatment, which could be changed at the patient’s 
screening visit for inclusion, but not thereafter. Patients 
were permitted to take drugs for other disorders, with 
some speciﬁ c exceptions (appendix). Diuretic treatment at 
screening was permitted if it could be discontinued during 
the 1 month run-in period and replaced with the randomly 
allocated diuretic. Patients who had not previously been 
treated for hypertension were eligible for inclusion 
provided that they were older than 55 years or black, or 
had a plasma renin concentration of less than 12 mU/L, or 
any combination thereof. Key exclusion criteria were 
diabetes diagnosed before enrolment, estimated 
glomerular ﬁ ltration rate of less than 45 mL/min per 
1·73m², and plasma potassium concentrations outside 
normal ranges (appendix). A full list of inclusion and 
exclusion criteria is provided in the appendix. All patients 
gave informed written consent. The protocol was approved 
by Cambridge South Ethics Committee.
Randomisation and masking
After a month’s placebo run-in, during which patients 
were masked to treatment, enrolled patients were 
randomly assigned (1:1:1) to 10 mg amiloride 
hydrochloride force-titrated to 20 mg, 25 mg 
hydrochlorothiazide force-titrated to 50 mg, or a 
combination of 5 mg amiloride plus 12·5 mg hydro-
chlorothiazide force-titrated to 10/25 mg orally daily. 
Doses were doubled in a single step after 12 weeks of 
treatment. Treatments were allocated according to 
randomly permuted blocks of size six with each treatment 
group appearing twice in each block. Randomisation was 
achieved via a computer-generated list of pseudo-random 
numbers in the Robertson Centre for Biostatistics 
(University of Glasgow, UK), which was the data 
management centre for the study. Complete blocks of 
treatment packs were allocated to study sites, thus 
ensuring balanced allocation of treatments within sites 
and over time. Treatment allocation was done by study 
nurses, who accessed a web-based randomisation system 
on a server in the Robertson Centre for Biostatistics.
All trial drugs were packed in identical containers by 
Alan Wong and colleagues at the Royal Free Hospital 
Pharmacy, London, UK, and labelled only by subject 
number and study phase. Investigators, laboratory staﬀ , 
and patients were masked to the identity of drugs 
(although the individual drugs, amiloride and 
hydrochlorothiazide, had a diﬀ erent appearance), and to 
their sequence allocation. All other antihypertensive 
drugs already being taken at the time of randomisation 
were continued unchanged and open-label.
Procedures
After randomisation, patients took the initial doses of 
their assigned drug for 12 weeks (phase 1). The doses 
were then doubled, and treatment continued for a further 
12 weeks (phase 2). An OGTT was done at baseline, 
12 weeks, and 24 weeks. Blood was taken at 0, 30, 60, and 
120 min after administration of a 75 g glucose drink; 
glucose was tested at all timepoints and insulin at 0 and 
30 min.
Other measurements were done at the same timepoints 
as the OGTTs. Seated home and clinic blood pressure 
were measured for each patient with their allocated, 
approved, automated blood pressure monitor (WatchBP 
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Home, Microlife; Clearwater, FL, USA) for the duration 
of the trial. Patients took home blood pressure readings 
in the morning and the evening in triplicate on 
4 consecutive days before each OGTT. Participants were 
instructed by specialist nurses in the use of the monitor, 
and training was reinforced at each clinic visit at which 
seated clinic blood pressure was measured—the mean of 
the last two measurements (three were taken). Before 
each OGTT, patients were also weighed, and had blood 
drawn for measurement of renin concentrations 
(analysed by the Diasorin Liaison automated 
chemiluminescent immunoassay for direct renin mass; 
Gerenzano, Italy22) and other biochemical parameters.
Outcomes
The primary outcome was the change from baseline in 
plasma glucose concentrations 2 h after oral administration 
of a 75 g glucose drink at 12 and 24 weeks.
The main secondary outcome was the change in home 
systolic blood pressure from baseline at at 12 and 24 weeks. 
Other secondary endpoints were changes in clinic systolic 
blood pressure, weight, electrolytes and calcium, uric acid, 
renin (as measure of natriuresis), HbA1c, insulin (at 0 and 
30 min during OGTT), area under the curve for glucose 
during OGTT, and lipid proﬁ le. Development of diabetes 
was deﬁ ned by fasting glucose concentrations ≥7 mmol/L 
or 2 h glucose concentrations ≥11∙1 mmol/L or HbA1c 
≥6∙5% (47∙5 mmol/mol).
Adverse events were recorded in free text at each visit, 
and coded by the data management centre on the basis of 
the medical dictionary for regulatory activities. Serious 
adverse events were documented and reported to the 
chief investigator and regulatory authorities, in 
accordance with local and national requirements.
Statistical analysis
Based on at least 80% power to detect a mean diﬀ erence 
in 2 h glucose between two treatment groups of 1 mmol/L 
(SD 2∙2) with two-sample t tests with a 1% signiﬁ cance 
level, 414 patients were needed. 1 mmol/L was the 
observed diﬀ erence in 2 h glucose concentrations in the 
largest previous trial of glucose intolerance caused by 
hydrochlorothiazide.18
To test both the mechanistic hypothesis—ie, that a 
potassium-sparing diuretic (amiloride) is better than a 
potassium-losing diuretic (hydrochlorothiazide) in terms of 
eﬀ ect on glucose tolerance—and that their combination is 
a practical alternative to hydro chlorothiazide monotherapy, 
663 patients screened
441 randomly assigned
145 assigned to amiloride 150 assigned to amiloride plus
 hydrochlorothiazide
146 assigned to
 hydrochlorothiazide 
132 patients in the modiﬁed
 intention-to-treat population
133 patients in the modiﬁed
 intention-to-treat population
134 patients in the modiﬁed
 intention-to-treat population
92 patients in the per-protocol
 population
92 patients in the per-protocol
 population
105 patients in the per-protocol
 population
13 no follow-up 17 no follow-up 12 no follow-up
16 deviated from trial protocol
29 discontinued treatment*
 16 adverse event
 8 investigator terminated
 4 unwilling to continue
 1 other
19 deviated from trial protocol
27 discontinued treatment*
 15 adverse event
   3 investigator terminated
   5 unwilling to continue
   4 other
15 deviated from trial protocol
18 discontinued treatment*
 11 adverse event
  1 investigator terminated
   3 unwilling to continue
   3 other
 
222 excluded
Figure 1: Trial proﬁ le
Patients who underwent at least one follow-up observation for the primary endpoint after randomisation were included in the modiﬁ ed intention-to-treat analyses. The 
appendix lists reasons for non-randomisation, dropout between randomisation and modiﬁ ed intention-to-treat populations, and “other” reasons for discontinuation of 
randomly assigned treatment. Reasons for exclusion from the per-protocol cohort are not mutually exclusive. *Some discontinuations were also protocol deviations, so 
the diﬀ erences between modiﬁ ed intention-to-treat and per-protocol populations are less than sum of protocol deviations and discontinuations.
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the study had two hier archical primary endpoints: we ﬁ rst 
compared 2 h glucose in the hydro chlorothiazide group 
with that of the amiloride group. If the diﬀ erence between 
the groups was signiﬁ cant, we then compared 2 h glucose 
in the hydrochlorothiazide group with the combination 
amiloride–hydrochlorothiazide group. Hierarchical analy-
sis prevents loss of power, because the prespeciﬁ ed ﬁ rst test 
needs to be positive before the next can be examined.
We tested for diﬀ erences between groups for primary 
and secondary endpoints by using mixed-eﬀ ect models to 
analyse continuous variables, with unstructured 
covariances for repeated measures within a patient, and 
adjustments for prespeciﬁ ed baseline covariates (sex, age, 
height, weight, smoking history, and the baseline value of 
the outcome being analysed). We estimated least-squares 
means for each treatment from these models, which are 
averaged from measurements at 12 and 24 weeks unless 
stated otherwise. We used similar models to assess 
baseline measurements that predicted response in 2 h 
glucose and home systolic blood pressure. We used 
logistic models to compare the proportion of patients who 
achieved target systolic blood pressure (deﬁ ned as 
≤140 mm Hg) at 24 weeks between the treatment groups 
and to compare the proportion of patients who developed 
diabetes by the end of the study between the three 
treatment groups. We used Fisher’s exact test for 
comparisons of adverse events between groups.
We used SAS (version 9.3) for our data analyses for the 
modiﬁ ed intention-to-treat population, which included 
all randomly assigned participants except for those with 
no primary outcome data from any follow-up visits. We 
included other participants for whom data were missing, 
and assumed that data were missing at random (ie, its 
absence was unrelated to the unobserved value). We did 
sensitivity analyses in the per-protocol population, which 
included participants who completed all follow-up visits 
with no major protocol deviation (adjudicated before 
breaking the study masking). The safety population, in 
whom the rate of adverse events and withdrawals was 
determined, was all randomised patients. There was no 
data monitoring board. This trial is registered with 
Clinicaltrials.gov, number NCT00797862 and the MHRA, 
Eudract number 2009-010068-41.
Role of the funding source
The funders of the study had no role in study design 
(other than through the peer-review process), the 
collection, analysis, or interpretation of the data, or the 
writing of the report. The corresponding author had full 
access to all the data and the ﬁ nal responsibility to submit 
for publication.
Results
Between Nov 18, 2009, and Dec 15, 2014 we screened 
663 patients and randomly assigned 441. 145 patients 
were assigned to the amiloride group, 146 to the 
hydrochlorothiazide group, and 150 to the amiloride–
hydrochlorothiazide combination group (ﬁ gure 1). The 
modiﬁ ed intention-to-treat analysis included 132 patients 
in the amiloride group, 134 patients in the hydro-
chlorothiazide group, and 133 patients in the amiloride 
plus hydrochlorothiazide group (ﬁ gure 1; appendix).
Table 1 shows baseline characteristics of the modiﬁ ed 
intention-to-treat population. The commonest indication 
for diuretic therapy was blood pressure uncontrolled by an 
ACE inhibitor or ARB, with more than 85% of participants 
in each group already taking these drugs. The commonest 
other component of the metabolic syndrome was central 
obesity, which was present in 99% of subjects.
The mean change from baseline in plasma glucose 
concentration at the 2 h timepoint during OGTT was 
Amiloride 
(n=132)
Amiloride plus 
hydrochlorothiazide 
(n=133)
Hydrochlorothiazide 
(n=134)
Age (years) 62·1 (10·4) 61·5 (10·2) 62·8 (9·9)
Female sex 52 (39·4%) 63 (47·4%) 47 (35·1%)
Weight (kg) 89·3 (16·7) 88·8 (16·7) 88·2 (17·1)
BMI (kg/m²) 31·4 (7·6) 31·0 (4·7) 30·6 (5·1)
Number of current smokers 10 (7·6%) 12 (9·0%) 15 (11·2%)
Blood pressure (mm Hg)
Clinic systolic 153·8 (11·4) 156·2 (12·4) 154·4 (11·7)
Clinic diastolic 91·3 (9·7) 91·2 (9·4) 90·0 (10·2)
Home systolic 149·3 (12·4) 150·6 (11·4) 148·8 (10·9)
Home diastolic 86·9 (9·8) 86·6 (8·9) 85·1 (9·6)
Previously untreated 7 (5·3%) 12 (9·0%) 11 (8·2%)
Receiving ACE inhibitor or ARB 119 (90·2%) 115 (86·5%) 117(87·3%)
Receiving β blocker 18 (13·6%) 24 (18·0%) 23 (17·2%)
Receiving calcium-channel blocker 56 (42·4%) 57 (42·9%) 56 (41·8%)
Number of drugs (if treated) 1·5 (0·7) 1·5 (0·7) 1·6 (0·7)
Central obesity* 129 (97·7%) 133 (100·0%) 132 (98·5%)
Serum potassium (mmol/L) 4·1 (0·4) 4·2 (0·3) 4·2 (0·4)
2 hour glucose during OGTT 
(mmol/L)
7·2 (2·3) 7·2 (2·1) 6·9 (2·4)
Impaired glucose tolerance† 44 (33·3%) 45 (33·8%) 42 (31·3%)
Data are mean (SD) or n (%). ACE=angiotensin-converting enzyme. ARB=angiotensin-receptor blocker. OGTT=oral 
glucose tolerance test. *Central obesity is deﬁ ned as a waist circumference of greater than 94 cm in men and greater than 
80 cm in women. †Impaired glucose tolerance is deﬁ ned as a 2 h glucose concentration of greater than 7·8 mmol/L. 
Table 1: Baseline characteristics in the modiﬁ ed intention-to-treat population
Amiloride 
(n=132)
Amiloride plus 
hydrochlorothiazide 
(n=133)
Hydrochlorothiazide 
(n=134)
Mean change from baseline 
(mmol/L)
–0·35 (–0·69 to –0·01) –0·22 (–0·56 to 0·11) 0·20 (–0·12 to 0·51)
Diﬀ erence from 
hydrochlorothiazide (mmol/L)
–0·55 (–0·96 to –0·14; 
p=0·0093)
–0·42 (–0·84 to 0·00;
p=0·048)
..
Data in parentheses are 95% CIs. Mean change from baseline was calculated on the basis of data at 12 weeks (low-dose 
treatment) and 24 weeks (high-dose treatment). Least squares estimates were adjusted for prespeciﬁ ed baseline 
covariates in a mixed-eﬀ ects model; p values are for comparisons with hydroclorothiazide. 
Table 2: Changes from baseline in 2 h glucose concentrations during oral glucose tolerance tests in the 
modiﬁ ed intention-to-treat population
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Unadjusted treatment means (95% CI) Adjusted treatment diﬀ erences (95% CI; p)
Amiloride 10–20 mg Combination amiloride/
hydrochlorothiazide 
5 mg/12·5 mg–10 mg/25 mg
Hydrochlorothiazide 
25–50 mg
Amiloride vs hydrochlorothiazide Combination vs 
hydrochlorothiazide
Home systolic blood pressure (mm Hg)
Baseline 149·3 (147·2 to 151·5) 150·6 (148·6 to 152·6) 148·8 (146·9 to 150·6) .. ..
12 weeks 138·3 (136·0 to 140·5) 136·1 (133·8 to 138·3) 138·5 (136·6 to 140·5) –0·5 (–3·2 to 2·1; p=0·70) –3·2 (–5·8 to –0·5; p=0·020)
24 weeks 134·4 (132·3 to 136·5) 132·3 (130·0 to 134·6) 135·0 (133·0 to 137·0) –1·0 (–3·7 to 1·7; p=0·49) –3·5 (–6·2 to –0·8; p=0·011)
Clinic systolic blood pressure (mm Hg)
Baseline 153·8 (151·9 to 155·8) 156·2 (154·0 to 158·3) 154·4 (152·4 to 156·4) .. ..
12 weeks 140·8 (138·5 to 143·1) 136·7 (134·2 to 139·3) 140·3 (137·7 to 142·9) 0·3 (–2·9 to 3·5; p=0·84) –3·9 (–7·1 to –0·7; p=0·016)
24 weeks 135·4 (132·9 to 137·9) 133·4 (131·0 to 135·8) 135·8 (133·3 to 138·2) –1·0 (–4·3 to 2·3; p=0·55) -4·0 (–7·2 to –0·7; p=0·018)
Bodyweight (kg)
Baseline 89·3 (86·4 to 92·1) 88·8 (85·9 to 91·7) 88·2 (85·3 to 91·1) .. ..
12 weeks 90·5 (87·6 to 93·5) 89·1 (86·2 to 92·1) 88·9 (85·9 to 91·8) 0·2 (–0·5 to 0·8; p=0·60) –0·2 (–0·8 to 0·5; p=0·64)
24 weeks 89·1 (85·9 to 92·2) 89·8 (86·4 to 93·2) 87·2 (84·3 to 90·0) –0·2 (–0·8 to 0·5; p=0·63) –0·1 (–0·8 to 0·6; p=0·82)
Renin (mU/L, log base 10)
Baseline 1·20 (1·09 to 1·31) 1·14 (1·03 to 1·24) 1·20 (1·11 to 1·30) .. ··
12 weeks 1·67 (1·53 to 1·80) 1·75 (1·61 to 1·89) 1·62 (1·50 to 1·74) 0·03 (–0·10 to 0·16; p=0·63) 0·21 (0·08 to 0·34; p=0·0018)
24 weeks 1·83 (1·70 to 1·95) 1·95 (1·82 to 2·09) 1·74 (1·62 to 1·86) 0·06 (–0·07 to 0·20; p=0·34) 0·25 0·12 to 0·39; p=0·0002)
Sodium (mmol/L)
Baseline 139·7 (139·3 to 140·2) 139·9 (139·5 to 140·4) 139·7 (139·2 to 140·2) ..
12 weeks 138·2 (137·8 to 138·6) 138·1 (137·7 to 138·5) 138·9 (138·5 to 139·3) –0·7 (–1·3 to –0·1; p=0·03) –1·1 (–1·7 to –0·4; p=0·0010)
24 weeks 138·1 (137·7 to 138·5) 138·0 (137·5 to 138·4) 138·6 (138·1 to 139·0) –0·6 (–1·2 to 0·1; p=0·097) –0·9 (–1·6 to –0·2; p=0·0075)
Potassium (mmol/L)
Baseline 4·09 (4·01 to 4·16) 4·16 (4·10 to 4·22) 4·21 (4·14 to 4·28) .. ..
12 weeks 4·55 (4·50 to 4·61) 4·31 (4·26 to 4·36) 3·97 (3·92 to 4·03) 0·68 (0·60 to 0·76; p<0·0001) 0·42 (0·34 to 0·50; p<0·0001)
24 weeks 4·61 (4·56 to 4·66) 4·17 (4·12 to 4·23) 3·79 (3·74 to 3·84) 0·90 (0·81 to 0·98; p<0·0001) 0·48 (0·39 to 0·56; p<0·0001)
Urea (mmol/L)
Baseline 5·36 (5·12 to 5·60) 5·15 (4·92 to 5·38) 5·40 (5·15 to 5·65) .. ..
12 weeks 5·90 (5·68 to 6·12) 6·08 (5·85 to 6·32) 6·03 (5·82 to 6·25) –0·02 (–0·31 to 0·28; p=0·91) 0·34 (0·05 to 0·64; p=0·024)
24 weeks 5·82 (5·59 to 6·06) 6·21 (5·98 to 6·44) 6·13 (5·87 to 6·39) –0·17 (–0·48 to 0·13; p=0·26) 0·45 (0·14 to 0·76; p=0·0042)
Creatinine (μmol/L)
Baseline 77·4 (74·4 to 80·4) 76·6 (73·3 to 79·9) 76·7 (73·8 to 79·6) .. ..
12 weeks 79·8 (77·5 to 82·2) 80·1 (77·6 to 82·7) 79·3 (76·9 to 81·6) 1·1 (–1·5 to 3·7; p=0·40) 2·3 (–0·4 to 4·9; p=0·089)
24 weeks 79·7 (77·2 to 82·3) 80·3 (77·7 to 83·0) 78·1 (75·6 to 80·6) 2·9 (0·2 to 5·6; p=0·03 3·8 (1·1 to 6·5; p=0·0057)
Uric acid (μmol/L)
Baseline 354 (340 to 369) 349 (332 to 365) 342 (324 to 359) .. ..
12 weeks 355 (340 to 371) 365 (347 to 383) 375 (358 to 392) –32 (–49 to –15; p=0·0003) –7 (–23 to 10; p=0·43)
24 weeks 351 (335 to 368) 380 (362 to 397) 392 (374 to 410) –50 (–67 to –33; p<0·0001) –3 (–20 to 14; p=0·76)
Total cholesterol (mmol/L)
Baseline 1·40 (1·27 to 1·52) 1·53 (1·37 to 1·69) 1·34 (1·23 to 1·46) .. ..
12 weeks 1·51 (1·34 to 1·68) 1·59 (1·42 to 1·76) 1·44 (1·30 to 1·58) 0·11 (–0·06 to 0·27; p=0·21) 0·10 (–0·07 to 0·26; p=0·25)
24 weeks 1·59 (1·40 to 1·77) 1·49 (1·35 to 1·63) 1·54 (1·39 to 1·69) 0·01 (–0·16 to 0·18; p=0·93) –0·16 (–0·33 to 0·01; p=0·057)
Triglycerides (mmol/L)
Baseline 1·40 (1·27 to 1·52) 1·53 (1·37 to 1·69) 1·34 (1·23 to 1·46) .. ..
12 weeks 1·51 (1·34 to 1·68) 1·59 (1·42 to 1·76) 1·44 (1·30 to 1·58) 0·11 (–0·06 to 0·27; p=0·21) 0·10 (–0·07 to 0·26; p=0·25)
24 weeks 1·59 (1·40 to 1·77) 1·49 (1·35 to 1·63) 1·54 (1·39 to 1·69) 0·01 (–0·16 to 0·18; p=0·93) –0·16 (–0·33 to 0·01; p=0·057)
LDL cholesterol (mmol/L)
Baseline 2·88 (2·70 to 3·05) 2·94 (2·78 to 3·10) 2·95 (2·79 to 3·11) .. ..
12 weeks 2·87 (2·71 to 3·03) 2·92 (2·75 to 3·09) 2·87 (2·72 to 3·03) –0·00 (–0·16 to 0·16; p=0·96) 0·07 (–0·09 to 0·23; p=0·3605)
24 weeks 3·05 (2·86 to 3·24) 2·95 (2·77 to 3·13) 2·96 (2·80 to 3·12) 0·10 (–0·06 to 0·26; p=0·22) 0·04 (–0·12 to 0·21; p=0·5849)
(Table 3 continues on next page)
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–0∙55 mmol/L (95% CI –0∙96 to –0∙14; p=0∙0093) in the 
amiloride group versus the hydro chloro thiazide group 
when 12 week and 24 week measurements were averaged 
(table 2). Because this diﬀ erence was signiﬁ cant, we then 
examined the other hierarchical primary endpoint: mean 
change from baseline in 2 h plasma glucose concentration 
in the combination group was signiﬁ cantly lower than 
that in the thiazide group (–0·42 [–0·84 to –0·004; 
p=0∙048).
Diﬀ erences in 2 h glucose concentrations between 
the hydrochlorothiazide group and the other groups 
increased with time and dose (ﬁ gure 2), and similar 
diﬀ erences were noted in the per-protocol population 
(appendix). The mean change in home systolic blood 
pressure averaged over 24 weeks was –12·9 mm Hg 
(95% CI –14·7 to —11·2) in the amiloride group, 
–12·2 mm Hg (–13·9 to –10·5) in the hydrochlorothiazide 
group, and –15·6 mm Hg (–17·3 to –13·8) in the 
combination group. The fall in home systolic blood 
pressure was 3∙4 mm Hg (0∙9 to 5∙8) greater in the 
combination than in the hydrochlorothiazide group 
(ﬁ gure 2B; p=0∙0068), averaged over 24 weeks. Mean 
changes in clinic systolic blood pressure during 
24 weeks did not diﬀ er signiﬁ cantly between the 
amiloride group (change from baseline –16·8 mm Hg 
[–18·8 to –14·8]) and the hydrochlorothiazide group 
(–16·5 mm Hg [–18·4 to –14·5]). In the combination 
group, systolic blood pressure fell by –20·4 mm Hg 
(–22·4 to –18·4), which was a signiﬁ cantly greater 
reduction compared with the hydrochlorothiazide 
group (between group diﬀ erence –3·9 mm Hg [–6·7 to 
–1·1], p=0∙0064). Blood pressures at each visit are 
shown in table 3. Blood pressure was more likely to be 
controlled by the combination than by hydro-
chlorothiazide monotherapy (odds ratio 1·77 [1·05 to 
2·96], p=0·031; appendix). The mean rise in renin 
concentrations was 1·69 (1·36 to 2·01, p<0∙0001) times 
higher at 12 and 24 weeks (average across the two 
timepoints) in the combination group than in the 
hydrochlorothiazide group (ﬁ gure 3A). Signiﬁ cant 
diﬀ erences were also noted in other markers of 
natriuresis, such as urea and creatinine concentrations, 
but not bodyweight (table 3).
Plasma potassium was unchanged at 24 weeks in the 
combination group, whereas a signiﬁ cant dose-
dependent rise in concentration was noted in the 
amiloride group (by 0·63 mmol/L [0·56 to 0·70]; 
p<0·0001 at 24 weeks) and a signiﬁ cant fall was recorded 
in the hydrochlorothiazide group (by –0·27 mmol/L 
[–0·34 to –0·20]; p<0·0001 at 24 weeks; ﬁ gure 3B). 
Plasma concentrations were signiﬁ cantly higher at 
24 weeks in both the amiloride and combination groups 
than in the hydrochlorothiazide group (p<0·0001 for 
both when adjusted for baseline covariates; ﬁ gure 3B).
Uric acid concentrations rose in the hydrochlorothiazide 
group but were unchanged in the amiloride group 
(p<0·0001 for diﬀ erence between groups; table 3, 
ﬁ gure 3C); uric acid concentrations did not diﬀ er 
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Figure 2: Changes in 2 h blood glucose concentrations (A), home systolic blood pressure (B), and clinic systolic blood pressure (C)
Data are adjusted means; error bars show 95% CIs. For (A), p=0·0026 for the comparison between the amiloride and hydrochlorothiazide groups and 0·039 for 
comparisons between the combination and hydrochlorothiazide groups at 24 weeks, in a model adjusting for baseline covariates. For (B), averaged across 12 weeks 
and 24 weeks, the fall in home blood pressure was signiﬁ cantly greater in the combination group than in the hydrochlorothiazide group (p=0·0068). For (C), averaged 
across 12 weeks and 24 weeks, the fall in clinic blood pressure was signiﬁ cantly greater in the combination group than in the hydrochlorothiazide group (p=0·0064).
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signi ﬁ cantly between the hydrochlorothiazide and com-
bination groups. Area under the curve during OGTT 
was signiﬁ cantly smaller in the amiloride group than 
in the hydrochlorothiazide group, but did not 
diﬀ er signiﬁ cantly between the combination and 
hydrochlorothiazide groups (table 3). We noted no 
signiﬁ cant diﬀ erences between groups in fasting 
glucose, insulin (at 0 and 30 min), HbA1c, or homoeostatic 
model assessment indices of insulin resistance and 
secretion (table 3), except for a diﬀ erence between the 
Unadjusted treatment means (95% CI) Adjusted treatment diﬀ erences (95% CI; p)
Amiloride 10–20 mg Combination amiloride/
hydrochlorothiazide 
5 mg/12·5 mg–10 mg/25 mg
Hydrochlorothiazide 
25–50 mg
Amiloride vs hydrochlorothiazide Combination vs 
hydrochlorothiazide
(Continued from previous page)
HDL cholesterol (mmol/L)
Baseline 1·27 (1·17 to 1·36) 1·33 (1·23 to 1·43) 1·35 (1·24 to 1·45) ..
12 weeks 1·17 (1·05 to 1·28) 1·34 (1·24 to 1·44) 1·35 (1·24 to 1·46) –0·18 (–0·34 to –0·03; p=0·018) –0·00 (–0·15 to 0·15; p=1·00)
24 weeks 1·20 (1·08 to 1·32) 1·32 (1·20 to 1·44) 1·35 (1·25 to 1·45) –0·13 (–0·28 to 0·02; p=0·09) –0·02 (–0·17 to 0·14; p=0·85)
Fasting glucose (mmol/L)
Baseline 5·20 (5·07 to 5·32) 5·13 (5·04 to 5·23) 5·30 (5·13 to 5·46) .. ..
12 weeks 5·30 (5·13 to 5·47) 5·26 (5·15 to 5·38) 5·38 (5·25 to 5·52) –0·00 (–0·16 to 0·16; p=0·98) –0·01 (–0·17 to 0·14; p=0·86)
24 weeks 5·23 (5·08 to 5·37) 5·27 (5·15 to 5·39) 5·39 (5·24 to 5·54) –0·08 (–0·23 to 0·08; p=0·36) –0·04 (–0·20 to 0·12; p=0·61)
2 h glucose (mmol/L)
Baseline 7·35 (6·87 to 7·82) 7·21 (6·84 to 7·59) 7·03 (6·62 to 7·44) .. ..
12 weeks 6·97 (6·59 to 7·35) 7·03 (6·66 to 7·41) 7·33 (6·98 to 7·69) –0·36 (–0·84 to 0·11; p=0·13) –0·30 (–0·78 to 0·18; p=0·21)
24 weeks 6·73 (6·35 to 7·10) 6·92 (6·55 to 7·30) 7·46 (7·11 to 7·81) –0·74 (–1·21 to –0·26; p=0·0023) –0·54 (–1·01 to –0·06; p=0·026)
Fasting insulin (pmol/L)
Baseline 80·1 (65·1 to 95·0) 86·2 (60·8 to 111·5) 95·6 (63·7 to 127·5) .. ..
12 weeks 85·1 (74·4 to 95·7) 121·1 (81·4 to 160·7) 101·9 (81·1 to 122·6) –17·0 (–46·1 to 12·0; p=0·25) –0·9 (–29·6 to 27·7; p=0·95)
24 weeks 88·7 (76·3 to 101·1) 107·7 (78·8 to 136·6) 102·1 (75·6 to 128·6) –17·7 (–47·5 to 12·1; p=0·24) 4·9 (–24·6 to 34·5; p=0·74)
30 min insulin (pmol/L)
Baseline 487 (368 to 605) 427 (379 to 474) 445 (378 to 512) .. ..
12 weeks 547 (448 to 645) 616 (484 to 748) 499 (431 to 568) 14 (–72 to 99; p=0·75) 68 (–14 to 150; p=0·10)
24 weeks 584 (488 to 680) 531 (437 to 626) 465 (397 to 533) 51 (–34 to 136; p=0·24) 88 (2 to 174; p=0·04)
Homoeostatic model assessment—insulin resistance
Baseline 2·70 (2·18 to 3·23) 2·93 (2·00 to 3·86) 3·29 (2·20 to 4·38) .. ..
12 weeks 2·90 (2·49 to 3·31) 4·34 (2·80 to 5·87) 3·57 (2·85 to 4·29) –0·65 (–1·84 to 0·55; p=0·29) 0·02 (–1·14 to 1·19; p=0·97)
24 weeks 3·01 (2·57 to 3·44) 3·88 (2·54 to 5·22) 3·57 (2·60 to 4·53) –0·84 (–2·05 to 0·37; p=0·17) 0·17 (–1·03 to 1·37; p=0·78)
Homoeostatic model assessment—β cells
Baseline 122·1 (98·6 to 145·7) 134·2 (103·1 to 165·2) 138·3 (93·1 to 183·4) .. ..
12 weeks 55·6 (43·8 to 67·4) 77·9 (54·0 to 101·8) 62·8 (47·7 to 77·9) –9·8 (–33·8 to 14·3; p=0·42) 13·8 (–10·2 to 37·8; p=0·26)
24 weeks 63·0 (47·1 to 79·0) 71·0 (54·4 to 87·5) 71·4 (51·0 to 91·8) –11·6 (–36·8 to 13·5; p=0·36) –2·9 (–28·0 to 22·3; p=0·82)
HbA1c (%)
Baseline 5·73 (5·63 to 5·83) 5·63 (5·55 to 5·70) 5·65 (5·57 to 5·74) .. ..
12 weeks 5·81 (5·70 to 5·91) 5·70 (5·62 to 5·78) 5·68 (5·54 to 5·82) 0·05 (–0·07 to 0·18; p=0·39) 0·05 (–0·07 to 0·17; p=0·38)
24 weeks 5·76 (5·64 to 5·88) 5·70 (5·60 to 5·81) 5·75 (5·65 to 5·85) –0·04 (–0·16 to 0·09; p=0·56) 0·00 (–0·12 to 0·13; p=0·95)
Calcium (mmol/L)
Baseline 2·34 (2·32 to 2·35) 2·33 (2·32 to 2·35) 2·32 (2·30 to 2·33) .. ..
12 weeks 2·30 (2·28 to 2·32) 2·31 (2·29 to 2·33) 2·29 (2·27 to 2·31) –0·01 (–0·04 to 0·02; p=0·62) 0·02 (–0·01 to 0·05; p=0·22)
24 weeks 2·31 (2·28 to 2·34) 2·32 (2·29 to 2·34) 2·31 (2·28 to 2·34) –0·01 (–0·04 to 0·02; p=0·46) 0·01 (–0·02 to 0·04; p=0·46)
Change in area under curve during oral glucose tolerance test
Baseline 987 (947 to 1027) 962 (931 to 992) 975 (941 to 1010) .. ..
12 weeks 951 (908 to 994) 965 (925 to 1005) 1005 (965 to 1046) –56 (–98 to –14; p=0·0087) –29 (–70 to 12; p=0·17)
24 weeks 930 (891 to 968) 975 (932 to 1018) 990 (947 to 1032) –60 (–103 to –18; p=0·0052) –20 (–63 to 23; p=0·37)
Comparisons are adjusted for baseline values. The slight diﬀ erences for 2 h glucose at week 24 between this table and table 2 arise because missing values were imputed in the calculations used for this table 
whereas they were omitted in table 2. To convert HbA1c to mmol/mol, multiply the percentages by 10·93 and subtract 23·5. To convert renin to pmol/L, multiply concentration in mU/L by 1·56. 
Table 3: Changes in blood pressure and biochemical parameters in the modiﬁ ed intention-to-treat population
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hydrochlorothiazide and combination groups for insulin 
at 30 min. However, we noted a mean numerical increase 
across all groups in HbA1c at both 12 weeks (0·086% 
[0·033–0·139], p=0·0006) and 24 weeks (0·126% 
[0·082–0·170], p<0·0001). 11 patients in the amiloride 
(11·8% adjusted for baseline covariates [95% CI 
6·3–21·1]), nine (8·0% [3·7–16·2]) in the combination, 
and 13 (12·6% [6·5–23·0]) in the hydrochlorothiazide 
group developed diabetes during the study. Odds ratios 
for developing diabetes compared with the 
hydrochlorothiazide group were 0∙65 (0∙25–1∙69) for 
the combination group and 1·07 (0·43–2·64) for the 
amiloride group.
Predictors of the glucose and blood pressure responses 
to study drugs are shown in the appendix. For change 
from baseline in 2 h glucose concentrations the main 
predictors were baseline fasting or 2 h glucose 
concentrations. For blood pressure, the main predictors 
were baseline blood pressure and plasma renin 
concentration. Blood glucose at the end of the study was 
weakly and inversely correlated with serum potassium 
concentrations (N=314, r²=0·02, p=0·010; no diﬀ erences 
between treatments [p=0·60]; appendix).
All drugs were well tolerated. 13 serious adverse events 
were reported. All adverse events are listed in the 
appendix. Only dizziness and muscle spasms were 
recorded in nine or more participants in each group; 
frequency of these events did not diﬀ er signiﬁ cantly 
between groups (table 4). Hyperkalaemia was reported 
in ten patients receiving amiloride alone or with 
hydrochlorothiazide (table 4). However the highest 
recorded potassium concentration was 5∙8 mmol/L (in 
the amiloride group), and most values were between 
5∙1 mmol/L and 5∙3 mmol/L (data not shown) in 
patients at a site where 5∙0 was the upper limit of the 
normal laboratory range (appendix).
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A B C
0
0
12
Time from baseline (weeks)
24
1
2
4
8
16
n-
fo
ld
 in
cr
ea
se
 in
 re
ni
n 
co
nc
en
tr
at
io
n
0
0 0
12
Time from baseline (weeks)
24
3·5
4·0
4·5
5
Se
ru
m
 p
ot
as
siu
m
 (m
m
ol
/L
)
0 12
Time from baseline (weeks)
24
320
330
340
350
360
370
380
390
400
410
420
Se
ru
m
 u
ric
 a
cid
 (μ
m
ol
/L
)
Figure 3: Changes in plasma renin (A), serum potassium (B), and serum uric acid (C) concentrations
Data for (A) are log-transformed changes from baseline; data for (B) and (C) are adjusted means. Error bars show 95% CIs. For (A), p=0·0002 for the comparison between 
the combination and hydrochlorothiazide groups at 24 weeks, from a model adjusting for baseline covariates. For (B), p<0·0001 for the comparison between the 
amiloride and the hydrochlorothiazide groups and between the combination and hydrochlorothiazide groups at 24 weeks, from a model adjusting for baseline 
covariates. For (C), p<0·0001 for the comparison between the amiloride and hydrochlorothiazide groups at 24 weeks, from a model adjusting for baseline covariates.
Amiloride (n=145) Amiloride plus 
hydrochlorothiazide (n=150)
Hydrochlorothiazide 
(n=146)
Amiloride vs 
hydrochlorothizaide
Combination vs 
hydrochlorothiazide
Withdrawals 17 (11·7%) 16 (10·7%) 10 (6·8%) 0·16 0·31
Serious adverse events 7 (4·8%) 4 (2·7%) 2 (1·4%) 0·10 0·68
Any adverse event 97 (66·9%) 92 (61·3%) 95 (65·1%) 0·80 0·55
Dizziness 9 (6·2%) 15 (10·0%) 16 (11·0%) 0·21 0·85
Muscle spasms 12 (8·3%) 14 (9·3%) 10 (6·8%) 0·66 0·52
Hyperkalaemia 7 (4·8%) 3 (2·0%) 0 0·0071 0·25
Data are n (%) unless otherwise speciﬁ ed. Fisher’s exact test was used to calculate p values. 
Table 4: Adverse events and withdrawals in the modiﬁ ed intention-to-treat population
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Discussion
Diuretics have been used as the control drug in many 
large hypertension studies, but have rarely in the past 
10 years been the main target of interest or studied in 
maximally eﬃ  cacious doses.23,24 Our study provides 
answers to several questions about diuretics that had not 
been previously investigated or resolved. We showed that, 
after 24 weeks of treatment, a potassium-sparing diuretic 
reduces blood pressure as eﬃ  caciously as high-dose 
thiazide without inducing adverse eﬀ ects on blood glucose 
concentrations. Furthermore, a combination of half the 
conventional doses of amiloride and hydrochlorothiazide 
was not associated with increased 2 h glucose con-
centrations compared with hydrochlorothiazide treatment 
alone but produced signiﬁ cantly larger reductions in 
blood pressure than full doses of either diuretic given 
alone. Amiloride monotherapy did not cause clinically 
signiﬁ cant hyperkalaemia, and the amiloride–
hydrochlorothiazide combination did not signiﬁ cantly 
aﬀ ect potassium concentrations.
Hitherto, the mechanism and prospects for prevention 
of thiazide-induced glucose intolerance were uncertain; 
the role of potassium in this problem was also unclear. A 
National Heart, Lung, and Blood Institute working party 
in 2008 identiﬁ ed potassium as “perhaps the most 
attractive variable” in developing a hypothesis for the 
mechanism of the thiazide response, and called for 
studies of potassium-sparing diuretics, among others.6 
Amiloride has been licensed for hypertension for almost 
as long as hydrochlorothiazide, but has rarely been used 
or studied in doses that lower blood pressure as eﬀ ectively 
as high-dose thiazides or other diuretic classes.25 That 
matched doses of thiazides and potassium-sparing 
diuretics, with similar eﬃ  cacy on blood pressure, could 
neutralise the undesirable eﬀ ects of each class while 
synergising to enhance reduction of blood pressure was 
an attractive hypothesis, but there were many unknowns, 
such as whether amiloride—in the context of blockade of 
the RAS in most patients—could be safely used at a dose 
large enough to match the blood pressure reduction of 
hydrochlorothiazide without causing hazardous 
electrolyte abnormalities.
Glucose concentration at 2 h in the OGTT is the best 
single measure for prediction of the long-term 
development of diabetes,26–28 and is also a strong predictor 
of cardiovascular morbidity.29 Sequential OGTTs oﬀ ered 
the possibility of testing the hypothesis that prevention 
of potassium depletion would protect against thiazide-
induced glucose intolerance. Although some of the 
diﬀ erence in glucose proﬁ les between the groups was 
due to a progressive increase in glucose intolerance in 
the hydrochlorothiazide group, glucose concentrations 
fell signiﬁ cantly in the amiloride group, at least when 
12 week and 24 week data were compared with baseline. 
The importance of even minor degrees of glucose 
intolerance has been long evident from the Whitehall 
study,30 which showed that, during a period of 7·5 years, 
mortality from coronary heart disease doubled in 
participants with a 2 h glucose concentration greater 
than 5·3 mmol/L compared with patients with 2 h 
concentations of less than 5·3 mmol/L. 
That amiloride and hydrochlorothiazide have opposite 
eﬀ ects on glucose tolerance is consistent with potassium 
depletion being the cause of the rise in blood glucose 
concentration in patients taking thiazide diuretics. The 
poor correlation in our study between plasma glucose 
and potassium might be related to how poorly plasma 
electrolytes reﬂ ect overall electrolyte balance—plasma 
potassium concentrations are often normal in primary 
aldosteronism, for example.31 However, we included an 
intermediate, combination group in the study, both to 
conﬁ rm the role of potassium and to investigate a 
treatment that could be implemented in practice. The 
combination group necessitated selection of doses of 
each drug that, unlike the available ﬁ xed-dose 
combinations (in which the dose of amiloride is only a 
tenth that of hydrochlorothiazide), were predicted to 
neutralise changes in potassium. If the eﬀ ects on blood 
glucose concentrations in the combination group were, 
as we noted with potassium concentrations, halfway 
between those in the two monotherapy groups, an even 
larger study than PATHWAY-3 would have been needed. 
But our additional predictions were that blood pressure 
would trump other eﬀ ects on blood glucose, and that 
combining half doses of two diuretics with diﬀ erent 
targets in the kidney would have synergistic eﬀ ects on 
sodium excretion, hence leading to reduction in blood 
pressure.
Our prediction of natriuretic synergism seems to be 
conﬁ rmed by the signiﬁ cantly greater reduction in 
home and clinic systolic blood pressure in the 
combination group than in the hydrochlorothiazide 
group. The blood pressure reduction in the combination 
group was associated with a near-doubling of the 
reactive rise in renin concentrations compared with 
those in the other two groups. This rise in renin 
concentrations is not clinically important in patients 
taking RAS blockers, but is a sensitive measure of 
natriuresis.32 Results of cross-sectional studies33,34 have 
suggested the importance of blood pressure control in 
the prevention of glucose intolerance, which might be 
underestimated in comparisons of diﬀ erent anti-
hypertensive drug classes. In studies of single 
antihypertensive drugs versus placebo, the reduced 
incidence of diabetes might be ascribed to the speciﬁ c 
class eﬀ ect rather than reductions in blood pressure 
reduction.35 The results of our pilot crossover studies 
showed that drugs that impair glucose tolerance when 
used alone (ie, β blockers and thiazide diuretics) have a 
neutral eﬀ ect on glucose tolerance when combined with 
each other, and that the more favourable eﬀ ects of the 
combination (compared with monotherapy) on glucose 
tolerance is associated with superior blood pressure 
reduction.19 Therefore the more eﬃ  cacious blood 
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pressure reduction in the amiloride–hydrochlorothiazide 
group compared with either drug alone is probably what 
underpins the success of the combination in avoiding 
induction of glucose intolerance.
The main limitation of our study is the short duration. 
24 weeks was long enough to test the hypotheses that 
drugs with opposite eﬀ ects on potassium concentrations 
would have opposite eﬀ ects on 2 h glucose concentrations, 
and that diuretics with diﬀ erent sites of action would 
have synergistic eﬀ ects on sodium loss, leading to blood 
pressure reduction, leading to glucose tolerance. 
However, not all patients who had a rise in 2 h glucose 
concentration in our study will progress to diabetes, and 
our results cannot show that longer-term usage of 
potassium-sparing diuretics will prevent an increase in 
incidence of diabetes as that which occurs with thiazide 
diuretics. Furthermore, 24 weeks’ exposure is not 
suﬃ  cient to provide complete assurance of long-term 
safety when amiloride is added to an RAS blocker—
intermittent monitoring of electrolytes and estimated 
glomerular ﬁ ltration rates will be necessary in practice.
The short duration of the study also limits our ability to 
explain why potassium-sparing and potassium-losing 
diuretics have opposing eﬀ ects on blood glucose. On 
several measures—insulin concentrations, HbA1c, and 
the calculated homoeostatic model assessments of 
insulin secretion and resistance—we found no 
diﬀ erences between groups. Good control of blood 
pressure and the high prevalence of ACE inhibitors or 
ARBs in our study population probably mitigated the rise 
in 2 h blood glucose in the hydrochlorothiazide group, 
despite the high proportion of patients with central 
adiposity.33–35 But results in the amiloride group—in 
which there were seemingly contrary trends for HbA1c 
and 2 h glucose concentrations—show previously noted 
limitations of using HbA1c as a surrogate of glucose 
intolerance.36 Thus, the adverse eﬀ ect of spironolactone 
on glucose tolerance, which was imputed from a similar 
small rise in HbA1c, could possibly be an artifact.37 The 
mechanism to explain why HbA1c does not accurately 
reﬂ ect glucose intolerance in this setting can only be 
speculated, but perhaps redistribution and reduction of 
blood supply by diuretics aﬀ ects red cell disposal and 
hence the turnover of HbA1c. A ﬁ nal limitation is that we 
enrolled patients with an increased likelihood of 
developing glucose intolerance. The beneﬁ cial eﬀ ects of 
amiloride might be less certain or applicable in thinner 
patients.
Diuretics are the oldest among commonly used 
antihypertensive drugs, and their target (sodium 
retention) is one of the few universally agreed 
contributors to the pathogenesis of hypertension.1 Yet 
they have slipped in priority in some guidelines, partly 
because of trials in which suboptimum doses of diuretics 
were compared with optimum doses of other classes, and 
partly because of thiazide-induced diabetes. Even if 
thiazide-induced diabetes does not carry the same 
cardiovascular risks as spontaneous diabetes, diuretics 
cease to be cost eﬀ ective when extra clinic visits and 
treatments for diabetes are factored into analyses.38 On 
the basis of our results from PATHWAY-3, we 
recommend that the combination of amiloride and 
hydrochlorothiazide, in doses equipotent for blood 
pressure reduction, becomes the ﬁ rst-choice diuretic in 
patients in whom adequate diuretic has not yet been 
prescribed. Our results suggest that this drug 
combination will confer the proven long-term beneﬁ ts of 
hydrochlorothiazide without the possible downside of 
glucose intolerance. Low doses of amiloride with 
hydrochlorothiazide in the INSIGHT trial13 were as 
eﬃ  cacious as nifedipine in the prevention of stroke and 
myocardial infarction, and signiﬁ cantly more eﬃ  cacious 
in the prevention of heart failure. In the Medical Research 
Council’s Elderly trial,17 the combination was signiﬁ cantly 
superior to atenolol in all cardiovascular endpoints.17 On 
the basis of our ﬁ ndings, the combination of 
hydrochlorothiazide with four times as much amiloride 
as was used in these studies can be predicted to increase 
its antihypertensive eﬃ  cacy and counter the risks and 
costs of hypokalaemia and glucose intolerance. The 
eﬃ  cacy of potassium-sparing diuretics revealed by 
PATHWAY-3, and the parallel PATHWAY-2 study of 
spironolactone in patients with resistant hypertension,39 
warrants investigation of their long-term beneﬁ ts in 
hypertension. 
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